1 / 20

TOC - Global Microbiome Therapeutics Market

The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032.<br>

bisreports
Télécharger la présentation

TOC - Global Microbiome Therapeutics Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Global Microbiome Therapeutics Market- A Global and Regional Analysis res Table of Content GLOBAL MICROBIOME THERAPEUTICS MARKET Focus on Target Therapies, Region (10 Countries), and Competitive Landscape Analysis and Forecast: 2022-2032 June 2022 1 All rights reserved at BIS Research Inc.

  2. BIS Research is a leading market intelligence and technology research company. BIS Research publishes in- depth market intelligence reports focusing on the market estimations, technology analysis, emerging high- growth applications, deeply segmented granular country-level market data and other important market parameters useful in the strategic decision making for senior management. BIS Research provides multi-client reports, company profiles, databases, and custom research services. GLOBAL MICROBIOME THERAPEUTICS MARKET Copyright © 2022 BIS Research Inc. All Rights Reserved. This document contains highly confidential information and is the sole property of BIS Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people or organization concerned. It may not be accessed by or offered, whether for sale or otherwise, to any third party. 2 All rights reserved at BIS Research Inc.

  3. Table of Content Executive Summary .......................................................................... 20 1.Market Definition ....................................................................... 24 1.1 Inclusion and Exclusion Criteria .................................................................... 24 2.Research Scope ........................................................................ 25 2.1 Target Audience ............................................................................................... 26 2.2 Key Questions Answered in the Report......................................................... 27 3.Research Methodology .............................................................. 28 3.1 Global Microbiome Therapeutics: Research Methodology .......................... 28 3.2 Primary Data Sources ..................................................................................... 29 3.3 Secondary Data Sources ................................................................................ 29 3.4 Market Estimation Model ................................................................................. 30 3.5 Criteria for Company Profiling ........................................................................ 32 4.Market Overview ........................................................................ 33 4.1 Market Size and Future Growth Potential ...................................................... 33 4.2 Historical Trends ............................................................................................. 34 5.Industry Insights ........................................................................ 35 5.1 Regulatory Landscape .................................................................................... 35 5.1.1Regulatory Requirements for Live Biotherapeutic Products (LBPs) ...... 35 5.1.2Quality Check of LBPs ................................................................................ 35 GLOBAL MICROBIOME THERAPEUTICS MARKET 5.1.3FDA Approved Fecal Microbiota Transplantation (FMT) Quality Check Procedure ......................................................................................... 36 5.2 Patent Landscape ............................................................................................ 37 5.2.1Patent Filing Analysis ................................................................................. 37 5.2.2Key Players Patent Portfolio ...................................................................... 38 5.2.3Key Players Patent Expiration Analysis .................................................... 40 5.3 Partnership Landscape ................................................................................... 41 5.4 Government Initiatives .................................................................................... 42 5.5 Impact of COVID-19 on the Global Microbiome Therapeutics Market ......... 44 5.5.1Clinical Trial Disruptions and Resumptions ............................................. 44 3 All rights reserved at BIS Research Inc.

  4. 6.Market Dynamics ....................................................................... 46 6.1 Market Drivers .................................................................................................. 46 6.1.1Growing Strategic Activities in Microbiome Therapeutics Segment ...... 46 6.1.2Potential of Microbiome Therapeutics to Address Unmet Needs of Existing Treatment Options ........................................................................ 47 6.1.3Microbiome Therapeutic Products as a Safer Alternative to Conventional Drug Treatments .................................................................. 47 6.2 Market Restraints ............................................................................................. 48 6.2.1Lack of Uniformed Standardized Regulatory Guidelines ......................... 48 6.2.2Associated Safety Issues with LBPs ......................................................... 48 6.2.3Storage Issues with Live Micro-Organisms .............................................. 48 6.2.4Challenges Associated with Manufacturing of LBPs ............................... 48 6.3 Market Opportunities ....................................................................................... 49 6.3.1Need for Current Good Manufacturing Practice (cGMP) Certified Contract Manufacturing Facilities .............................................................. 49 6.3.2Growing Disease Dimension ...................................................................... 49 6.3.3Entry of Major Players ................................................................................. 49 7.Clinical Trial Landscape ............................................................. 50 7.1 Microbiome Therapeutics Pipeline Landscape ............................................. 50 7.1.1Competitive Landscaping ........................................................................... 50 7.1.2Pipeline Analysis ......................................................................................... 54 GLOBAL MICROBIOME THERAPEUTICS MARKET 7.1.2.1 By Development Phase ..................................................................................... 54 7.1.2.2 By Route of Administration ................................................................................ 55 7.1.2.3 By Type of Microbiome Strategy ........................................................................ 56 7.1.2.4 By Indication ...................................................................................................... 57 7.1.3Emerging Microbiome Therapeutics Products ......................................... 58 7.2 Probable Potential First Entrants to Global Microbiome Therapeutics Market/ Microbiome Therapeutics Clinical Trial Design ............................... 62 7.2.1CP-101 (Finch Therapeutics Group, Inc.) .................................................. 63 7.2.1.1 CP-101: Product Profile ..................................................................................... 63 7.2.2SER-109 (Seres Therapeutics, Inc.) ........................................................... 65 4 All rights reserved at BIS Research Inc.

  5. 7.2.2.1 SER-109: Product Profile ................................................................................... 65 7.2.3RBX-2660 (Rebiotix Inc.) ............................................................................. 68 7.2.3.1 RBX-2660: Product Profile ................................................................................. 68 7.2.4CH-106 (Caelus Health) ............................................................................... 71 7.2.4.1 CH-106: Product Profile ..................................................................................... 71 7.2.5LACTIN-V (Osel Inc.) ................................................................................... 73 7.2.5.1 LACTIN-V: Product Profile ................................................................................. 73 7.2.6MaaT013 (MaaT Pharma) ............................................................................. 73 7.2.6.1 MaaT013: Product Profile .................................................................................. 73 8.Competitive Insights .................................................................. 74 8.1 Key Strategies and Developments ................................................................. 74 8.2 Synergistic Activities ...................................................................................... 74 8.3 Product Launch and Regulatory Approvals .................................................. 75 8.4 Funding and Investment ................................................................................. 76 8.5 Mergers and Acquisitions ............................................................................... 77 8.6 Market Share Analysis .................................................................................... 78 8.7 Growth-Share Analysis (Opportunity Mapping) ............................................ 79 8.7.1By Region ..................................................................................................... 79 8.7.2By Company ................................................................................................ 80 9.Global Microbiome Therapeutics Market (by Target Therapy Area) ......................................................................................... 82 GLOBAL MICROBIOME THERAPEUTICS MARKET 9.1 Overview ........................................................................................................... 82 9.2 Gastrointestinal and Infectious Diseases ...................................................... 83 9.3 Skin Disorders ................................................................................................. 85 9.4 Cancer Indications ........................................................................................... 87 Other Indications ............................................................................................. 88 10.Global Microbiome Therapeutics Market (by Region) ................. 89 9.5 10.1.1Overview ...................................................................................................... 89 10.2North America .................................................................................................. 90 10.2.1Overview ...................................................................................................... 90 5 All rights reserved at BIS Research Inc.

  6. 10.2.2U.S. ............................................................................................................... 93 10.2.3Canada ......................................................................................................... 94 10.3Europe .............................................................................................................. 95 10.3.1Overview ...................................................................................................... 95 10.3.2France ........................................................................................................... 98 10.3.3Germany ....................................................................................................... 99 10.3.4Sweden ....................................................................................................... 100 10.3.5U.K. ............................................................................................................. 101 10.3.6Italy ............................................................................................................. 102 10.3.7Spain ........................................................................................................... 102 10.3.8Rest-of-Europe........................................................................................... 103 10.4Asia-Pacific (APAC) ....................................................................................... 104 10.4.1Overview .................................................................................................... 104 10.4.2Japan .......................................................................................................... 106 10.4.3Australia ..................................................................................................... 107 10.4.4China .......................................................................................................... 109 10.4.5India ............................................................................................................ 110 10.4.6Rest-of-Asia-Pacific ................................................................................... 111 10.5Rest-of-the-World .......................................................................................... 112 10.5.1Overview .................................................................................................... 112 11.Competitive Benchmarking and Company Profiles ................... 113 GLOBAL MICROBIOME THERAPEUTICS MARKET 11.14D pharma plc ................................................................................................ 113 11.1.1Company Overview ................................................................................... 113 11.1.2Role of 4D pharma plc in the Global Microbiome Therapeutics Market ......................................................................................................... 113 11.1.3Key Competitors of the Company ............................................................ 114 11.1.4Financials ................................................................................................... 115 11.1.5Recent Developments ............................................................................... 116 11.1.6Analyst’s Perspective ............................................................................... 116 11.2Seres Therapeutics, Inc. ............................................................................... 118 6 All rights reserved at BIS Research Inc.

  7. 11.2.1Company Overview ................................................................................... 118 11.2.2Role of Seres Therapeutics, Inc. in the Global Microbiome Therapeutics Market .................................................................................. 118 11.2.3Key Competitors of the Company ............................................................ 119 11.2.4Financials ................................................................................................... 119 11.2.5Recent Developments ............................................................................... 121 11.2.6Analyst Perspective .................................................................................. 121 11.3Microbiotica .................................................................................................... 122 11.3.1Company Overview ................................................................................... 122 11.3.2Role of Microbiotica in the Global Microbiome Therapeutics Market .............................................................................................................. 122 11.3.3Key Competitors of the Company ............................................................ 123 11.3.4Recent Developments ............................................................................... 123 11.3.5Analyst’s Perspective ............................................................................... 123 11.4Enterome ........................................................................................................ 124 11.4.1Company Overview ................................................................................... 124 11.4.2Role of Enterome in the Global Microbiome Therapeutics Market ....... 124 11.4.3Key Competitors of the Company ............................................................ 125 11.4.4Recent Developments ............................................................................... 125 11.4.5Analyst’s Perspective ............................................................................... 125 11.5Destiny Pharma plc ....................................................................................... 126 GLOBAL MICROBIOME THERAPEUTICS MARKET 11.5.1Company Overview ................................................................................... 126 11.5.2Role of Destiny Pharma plc in the Global Microbiome Therapeutics Market ......................................................................................................... 126 11.5.3Key Competitors of the Company ............................................................ 127 11.5.4Financials ................................................................................................... 127 11.5.5Recent Developments ............................................................................... 128 11.5.6Analyst’s Perspective ............................................................................... 129 11.6Taisho Pharmaceutical Holdings ................................................................. 130 11.6.1Company Overview ................................................................................... 130 7 All rights reserved at BIS Research Inc.

  8. 11.6.2Role of Taisho Pharmaceutical Holdings in the Global Microbiome Therapeutics Market .................................................................................. 130 11.6.3Key Competitors of the Company ............................................................ 131 11.6.4Financials ................................................................................................... 131 11.6.5Recent Developments ............................................................................... 134 11.6.6Analyst’s Perspective ............................................................................... 134 11.7AOBiome Therapeutics, Inc. ......................................................................... 135 11.7.1Company Overview ................................................................................... 135 11.7.2Role of AOBiome Therapeutics, Inc. in the Global Microbiome Therapeutics Market .................................................................................. 135 11.7.3Key Competitors of the Company ............................................................ 136 11.7.4Recent Developments ............................................................................... 136 11.7.5Analyst’s Perspective ............................................................................... 136 11.8Finch Therapeutics Group, Inc. .................................................................... 137 11.8.1Company Overview ................................................................................... 137 11.8.2Role of Finch Therapeutics Group, Inc. in the Global Microbiome Therapeutics Market .................................................................................. 137 11.8.3Key Competitors of the Company ............................................................ 138 11.8.4Financials ................................................................................................... 138 11.8.5Recent Developments ............................................................................... 140 11.8.6Analyst’s Perspective ............................................................................... 140 GLOBAL MICROBIOME THERAPEUTICS MARKET 11.9Ferring Pharmaceuticals ............................................................................... 141 11.9.1Company Overview ................................................................................... 141 11.10Rebiotix Inc. (A Subsidiary of Ferring Pharmaceuticals) ........................... 141 11.10.1 Company Overview ............................................................................. 141 11.10.2 Role of Rebiotix Inc. in the Global Microbiome Therapeutics Market ......................................................................................................... 141 11.10.3 Key Competitors of the Company ..................................................... 142 11.10.4 Recent Developments ......................................................................... 142 11.10.5 Analyst’s Perspective ......................................................................... 143 11.11MaaT Pharma ................................................................................................. 144 8 All rights reserved at BIS Research Inc.

  9. 11.11.1 Company Overview ............................................................................. 144 11.11.2 Role of MaaT Pharma in the Global Microbiome Therapeutics Market ......................................................................................................... 144 11.11.3 Key Competitors of the Company ..................................................... 145 11.11.4 Financials ............................................................................................ 145 11.11.5 Recent Developments ......................................................................... 146 11.11.6 Analyst’s Perspective ......................................................................... 146 11.12Vedanta Biosciences Inc. .............................................................................. 147 11.12.1 Company Overview ............................................................................. 147 11.12.2 Role of Vedanta Biosciences Inc. in the Global Microbiome Therapeutics Market .................................................................................. 147 11.12.3 Key Competitors of the Company ..................................................... 148 11.12.4 Recent Developments ......................................................................... 148 11.12.5 Analyst’s Perspective ......................................................................... 148 11.13OxThera AB .................................................................................................... 149 11.13.1 Company Overview ............................................................................. 149 11.13.2 Role of OxThera AB in the Global Microbiome Therapeutics Market ......................................................................................................... 149 11.13.3 Key Competitors of the Company ..................................................... 150 11.13.4 Recent Developments ......................................................................... 150 11.13.5 Analyst’s Perspective ......................................................................... 150 GLOBAL MICROBIOME THERAPEUTICS MARKET 11.14Pendulum Therapeutics ................................................................................ 151 11.14.1 Company Overview ............................................................................. 151 11.14.2 Role of Pendulum Therapeutics in the Global Microbiome Therapeutics Market .................................................................................. 151 11.14.3 Key Competitors of the Company ..................................................... 152 11.14.4 Recent Developments ......................................................................... 152 11.14.5 Analyst’s Perspective ......................................................................... 152 11.15Caelus Health ................................................................................................. 153 11.15.1 Company Overview ............................................................................. 153 9 All rights reserved at BIS Research Inc.

  10. 11.15.2 Role of Caelus Health in the Global Microbiome Therapeutics Market ......................................................................................................... 153 11.15.3 Key Competitors of the Company ..................................................... 154 11.15.4 Recent Developments ......................................................................... 154 11.15.5 Analyst’s Perspective ......................................................................... 154 11.16Quorum Innovations ...................................................................................... 156 11.16.1 Company Overview ............................................................................. 156 11.16.2 Role of Quorum Innovations in the Global Microbiome Therapeutics Market .................................................................................. 156 11.16.3 Key Competitors of the Company ..................................................... 157 11.16.4 Recent Developments ......................................................................... 157 11.16.5 Analyst’s Perspective ......................................................................... 157 11.17Sanofi S.A. ...................................................................................................... 158 11.17.1 Company Overview ............................................................................. 158 11.17.2 Role of Sanofi S.A. in the Global Microbiome Therapeutics Market ......................................................................................................... 158 11.17.3 Key Competitors of the Company ..................................................... 159 11.17.4 Financials ............................................................................................ 159 11.17.5 Recent Developments ......................................................................... 161 11.17.6 Analyst’s Perspective ......................................................................... 162 11.18DermBiont, Inc. .............................................................................................. 163 GLOBAL MICROBIOME THERAPEUTICS MARKET 11.18.1 Company Overview ............................................................................. 163 11.18.2 Role of DermBiont, Inc. in the Global Microbiome Therapeutics Market ......................................................................................................... 163 11.18.3 Key Competitors of the Company ..................................................... 164 11.18.4 Recent Developments ......................................................................... 164 11.18.5 Analyst’s Perspective ......................................................................... 164 11.19EnteroBiotix Ltd ............................................................................................. 166 11.19.1 Company Overview ............................................................................. 166 11.19.2 Role of EnteroBiotix Ltd in the Global Microbiome Therapeutics Market ......................................................................................................... 166 10 All rights reserved at BIS Research Inc.

  11. 11.19.3 Key Competitors of the Company ..................................................... 167 11.19.4 Recent Developments ......................................................................... 167 11.19.5 Analyst’s Perspective ......................................................................... 167 11.20YSOPIA Bioscience ....................................................................................... 168 11.20.1 Company Overview ............................................................................. 168 11.20.2 Role of YSOPIA Bioscience in the Global Microbiome Therapeutics Market .................................................................................. 168 11.20.3 Key Competitors of the Company ..................................................... 169 11.20.4 Recent Developments ......................................................................... 169 11.20.5 Analyst’s Perspective ......................................................................... 170 11.21Winclove Probiotics ...................................................................................... 171 11.21.1 Company Overview ............................................................................. 171 11.21.2 Role of Winclove Probiotics in the Global Microbiome Therapeutics Market .................................................................................. 171 11.21.3 Key Competitors of the Company ..................................................... 172 11.21.4 Recent Developments ......................................................................... 173 11.21.5 Analyst’s Perspective ......................................................................... 173 11.22TargEDys ........................................................................................................ 174 11.22.1 Company Overview ............................................................................. 174 11.22.2 Role of TargEDys in the Global Microbiome Therapeutics Market ......................................................................................................... 174 GLOBAL MICROBIOME THERAPEUTICS MARKET 11.22.3 Key Competitors of the Company ..................................................... 175 11.22.4 Recent Developments ......................................................................... 175 11.22.5 Analyst’s Perspective ......................................................................... 175 11.23Evelo Biosciences, Inc. ................................................................................. 176 11.23.1 Company Overview ............................................................................. 176 11.23.2 Role of Evelo Biosciences, Inc. in the Global Microbiome Therapeutics Market .................................................................................. 176 11.23.3 Key Competitors of the Company ..................................................... 177 11.23.4 Financials ............................................................................................ 178 11.23.5 Recent Developments ......................................................................... 179 11 All rights reserved at BIS Research Inc.

  12. 11.23.6 Analyst’s Perspective ......................................................................... 179 11.24BiomX ............................................................................................................. 180 11.24.1 Company Overview ............................................................................. 180 11.24.2 Role of BiomX in the Global Microbiome Therapeutics Market ...... 180 11.24.3 Key Competitors of the Company ..................................................... 181 11.24.4 Financials ............................................................................................ 181 11.24.5 Recent Developments ......................................................................... 182 11.24.6 Analyst’s Perspective ......................................................................... 182 11.25Biomica Ltd. ................................................................................................... 184 11.25.1 Company Overview ............................................................................. 184 11.25.2 Role of Biomica Ltd. in the Global Microbiome Therapeutics Market ......................................................................................................... 184 11.25.3 Key Competitors of the Company ..................................................... 185 11.25.4 Recent Developments ......................................................................... 185 11.25.5 Analyst’s Perspective ......................................................................... 185 11.26Scioto Biosciences, Inc. ................................................................................ 186 11.26.1 Company Overview ............................................................................. 186 11.26.2 Role of Scioto Biosciences, Inc. in the Global Microbiome Therapeutics Market .................................................................................. 186 11.26.3 Key Competitors of the Company ..................................................... 187 11.26.4 Recent Developments ......................................................................... 187 GLOBAL MICROBIOME THERAPEUTICS MARKET 11.26.5 Analyst’s Perspective ......................................................................... 188 11.27Lactobio A/S ................................................................................................... 189 11.27.1 Company Overview ............................................................................. 189 11.27.2 Role of Lactobio A/S in the Global Microbiome Therapeutics Market ......................................................................................................... 189 11.27.3 Key Competitors of the Company ..................................................... 190 11.27.4 Recent Developments ......................................................................... 190 Analyst’s Perspective ......................................................................... 191 12.Appendix ................................................................................. 192 11.27.5 12 All rights reserved at BIS Research Inc.

  13. List of Figures Figure 1: Global Microbiome Therapeutics Market Share (by Target Therapy Area), $Million, 2021 Figure 2: Global Microbiome Therapeutics Market Share (by Region), $Million, 2021 and 2032 Figure 3: Growth-Share Analysis (by Region), 2020-2021 Figure 4: Global Microbiome Therapeutics Market Segmentation Figure 5: Global Microbiome Therapeutics Market Methodology Figure 6: Primary Research Methodology Figure 7: Bottom-Up Approach (Segment Wise Analysis) Figure 8: Top-Down Approach (Segment-Wise Analysis) Figure 9: Global Microbiome Therapeutics Market, $Million, 2021-2032 Figure 10: Historical Evolution of Microbiome Therapeutics Figure 11: Chemistry, Manufacturing, and Control (CMC) Information of LBPs by FDA Figure 12: Patent Landscape of the Microbiome Therapeutics Market (by Region), 2019-2021 Figure 13: COVID-19 Impact on the Global Microbiome Therapeutics Market Figure 14: Number of Strategic Activities in the Global Microbiome Therapeutics Market, 2019-2021 Figure 15: Number of Agreements for Leading Companies Figure 16: Share of Microbiome Therapeutics Products in Global Clinical Trials (by Development Phase) Figure 17: Share of Microbiome Therapeutics Pipeline Candidates (by Route of Administration) Figure 18: Share of Microbiome Therapeutics Products (by Type of Microbiome Strategy) Figure 19: Number of Microbiome Therapeutic Products in Global Clinical Trials (by Indication) Figure 20: CP-101: Phase II Clinical Design for Recurrent C. diff. Infection (CDI) GLOBAL MICROBIOME THERAPEUTICS MARKET Figure 21: CP-101 Phase III Clinical Design for Recurrent C. diff. Infection (CDI) Figure 22: SER-109: Mechanism of Action Figure 23: SER-109: Clinical Trial Details for Recurrent C. diff. Infection (CDI) Figure 24: RBX-2660: Key Regulatory Milestones Figure 25: RBX-2660: Clinical Progress for Recurrent C. Diff Infection (CDI) Figure 26: RBX-2660: Clinical Trial Details for Recurrent C. diff. Infection (CDI) Figure 27: CH-106: Clinical Design for Metabolic Syndrome/Prediabetes Figure 28: Share of Key Developments and Strategies, January 2019–October 2021 Figure 29: Share of Synergistic Activities (by Company), January 2019-October 2021 Figure 30: Share of Product Launch and Regulatory Approvals (by Company), January 2019-October 2021 13 All rights reserved at BIS Research Inc.

  14. Figure 31: Share of Funding and Investment (by Company), January 2019-October 2021 Figure 32: Share of Mergers and Acquisitions (by Company), January 2019-October 2021 Figure 33: Market Share Analysis for the Global Microbiome Therapeutics Market, $Million, 2020 and 2021 Figure 34: Growth-Share Analysis (by Region), 2020-2021 Figure 35: Growth-Share Analysis (by Company), 2020-2021 Figure 36: Global Microbiome Therapeutics Market (by Target Therapy Area), $Million, 2021 and 2032 Figure 37: Number of Pipeline Candidates for Gastrointestinal and Infectious Diseases Figure 38: Global Microbiome Therapeutics Market (Gastrointestinal and Infectious Diseases), $Million, 2021-2032 Figure 39: Number of Pipeline Products for Skin Disorders Figure 40: Global Microbiome Therapeutics Market (Skin Disorders), $Million, 2021-2032 Figure 41: Number of Pipeline Products for Cancer Indications Figure 42: Number of Pipeline Products for Other Indications Figure 43: Global Microbiome Therapeutics Market (by Region), 2022-2032 Figure 44: Global Microbiome Therapeutics Market Share (by Region), $Million, 2021-2032 Figure 45: North America Microbiome Therapeutics Market, $Million, 2021-2032 Figure 46: North America: Market Dynamics Figure 47: North America Microbiome Therapeutics Market Share (by Country), $Million, 2021 and 2032 Figure 48: U.S. Microbiome Therapeutics Market, $Million, 2021-2032 Figure 49: Canada Microbiome Therapeutics Market, $Million, 2021-2032 Figure 50: Europe Microbiome Therapeutics Market, $Million, 2021-2032 Figure 51: Europe: Market Dynamics GLOBAL MICROBIOME THERAPEUTICS MARKET Figure 52: Europe Microbiome Therapeutics Market Share (by Country), $Million, 2021 and 2032 Figure 53: France Microbiome Therapeutics Market, $Million, 2021-2032 Figure 54: Germany Microbiome Therapeutics Market, $Million, 2021-2032 Figure 55: Sweden Microbiome Therapeutics Market, $Million, 2021-2032 Figure 56: U.K Microbiome Therapeutics Market, $Million, 2021-2032 Figure 57: Italy Microbiome Therapeutics Market, $Million, 2021-2032 Figure 58: Spain Microbiome Therapeutics Market, $Million, 2021-2032 Figure 59: Rest-of-Europe Microbiome Therapeutics Market, $Million, 2021-2032 Figure 60: Asia-Pacific Microbiome Therapeutics Market, $Million, 2021-2032 Figure 61: Asia-Pacific: Market Dynamics 14 All rights reserved at BIS Research Inc.

  15. Figure 62: Asia-Pacific Microbiome Therapeutics Market Share (by Country), $Million, 2021-2032 Figure 63: Japan Microbiome Therapeutics Market, $Million, 2021-2032 Figure 64: Australia Microbiome Therapeutics Market, $Million, 2021-2032 Figure 65: China Microbiome Therapeutics Market, $Million, 2021-2032 Figure 66: India Microbiome Therapeutics Market, $Million, 2021-2032 Figure 67: Rest-of-Asia-Pacific Microbiome Therapeutics Market, $Million, 2021-2032 Figure 68: Rest-of-the-World Microbiome Therapeutics Market, $Million, 2021-2032 Figure 69: 4D pharma plc: Product Portfolio Figure 70: 4D pharma plc: Overall Financials, $Million, 2019-2021 Figure 71: 4D pharma plc: R&D Expenditure, $Million, 2019-2021 Figure 72: Seres Therapeutics, Inc.: Product Portfolio Figure 73: Seres Therapeutics, Inc.: Overall Financials, $Million, 2019-2021 Figure 74: Seres Therapeutics, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 75: Microbiotica: Product Portfolio Figure 76: Enterome: Product Portfolio Figure 77: Destiny Pharma plc: Product Portfolio Figure 78: Destiny Pharma plc: Overall Financials, $Million, 2019-2021 Figure 79: Destiny Pharma plc: R&D Expenditure, $Million, 2019-2021 Figure 80: Taisho Pharmaceutical Holdings: Product Portfolio Figure 81: Taisho Pharmaceutical Holdings: Overall Financials, $Million, 2019-2021 Figure 82: Taisho Pharmaceutical Holdings: Net Revenue (by Segment), $Million, 2019-2021 Figure 83: Taisho Pharmaceutical Holdings: Net Revenue (by Region), $Million, 2019-2021 GLOBAL MICROBIOME THERAPEUTICS MARKET Figure 84: Taisho Pharmaceutical Holdings: R&D Expenditure, $Million, 2019-2021 Figure 85: AOBiome Therapeutics, Inc.: Product Portfolio Figure 86: Finch Therapeutics Group, Inc.: Product Portfolio Figure 87: Finch Therapeutics Group, Inc.: Overall Financials, $Million, 2019-2021 Figure 88: Finch Therapeutics Group, Inc.: R&D Expenditure, $Million, 2020-2021 Figure 89: Rebiotix Inc.: Product Portfolio Figure 90: MaaT Pharma: Product Portfolio Figure 91: MaaT Pharma: Overall Financials, $Million, 2020-2021 Figure 92: MaaT Pharma: R&D Expenditure, $Million, 2020-2021 Figure 93: Vedanta Biosciences Inc.: Product Portfolio Figure 94: OxThera AB: Product Portfolio 15 All rights reserved at BIS Research Inc.

  16. Figure 95: Pendulum Therapeutics: Product Portfolio Figure 96: Caelus Health: Product Portfolio Figure 97: Quorum Innovations: Product Portfolio Figure 98: Sanofi S.A.: Product Portfolio Figure 99: Sanofi S.A.: Overall Financials, $Million, 2019-2021 Figure 100: Sanofi S.A.: Net Revenue (by Segment), $Million, 2019-2021 Figure 101: Sanofi S.A.: Net Revenue by Region), $Million, 2019-2021 Figure 102: Sanofi S.A.: R&D Expenditure, $Million, 2019-2021 Figure 103: DermBiont, Inc.: Product Portfolio Figure 104: EnteroBiotix Ltd: Product Portfolio Figure 105: YSOPIA Bioscience: Product Portfolio Figure 106: Winclove Probiotics: Product Portfolio Figure 107: TargEDys: Product Portfolio Figure 108: Evelo Biosciences, Inc.: Product Portfolio Figure 109: Evelo Biosciences, Inc.: Pipeline Products Figure 110: Evelo Biosciences, Inc.: Overall Financials, $Million, 2019-2021 Figure 111: Evelo Biosciences, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 112: BiomX: Product Portfolio Figure 113: BiomX: Pipeline Products Figure 114: BiomX: Overall Financials, $Million, 2019-2021 Figure 115: BiomX: R&D Expenditure, $Million, 2019-2021 Figure 116: Biomica Ltd.: Pipeline Product GLOBAL MICROBIOME THERAPEUTICS MARKET Figure 117: Scioto Biosciences, Inc.: Product Portfolio Figure 118: Scioto Biosciences, Inc.: Pipeline Product Figure 119: Lactobio A/S: Product Portfolio Figure 120: Lactobio A/S: Pipeline Product 16 All rights reserved at BIS Research Inc.

  17. List of Tables Table 1: Global Microbiome Therapeutics Market: Key Players Patent Portfolio Table 2: Patent Expiration Analysis Table 3: Partnership Landscaping Table 4: Government Initiatives in Microbiome Therapeutics Table 5: Impact of COVID-19 on Microbiome Therapeutics Developing Companies Table 6: Key Players/Investors Portfolio Table 7: Emerging Microbiome Therapeutics Products Pipeline Table 8: Probable Potential First Entrants to Global Microbiome Therapeutics Market Table 9: 4D pharma plc: Key Competitors Table 10: Seres Therapeutics, Inc.: Key Competitors Table 11: Microbiotica: Key Competitors Table 12: Enterome: Key Competitors Table 13: Destiny Pharma plc: Key Competitors Table 14: Taisho Pharmaceutical Holdings: Key Competitors Table 15: AOBiome Therapeutics, Inc.: Key Competitors Table 16: Finch Therapeutics Group, Inc.: Key Competitors Table 17: Rebiotix Inc.: Key Competitors Table 18: MaaT Pharma: Key Competitors Table 19: Vedanta Biosciences Inc.: Key Competitors Table 20: Pendulum Therapeutics: Key Competitors GLOBAL MICROBIOME THERAPEUTICS MARKET Table 21: Caelus Health: Key Competitors Table 22: Quorum Innovations: Key Competitors Table 23: Sanofi S.A.: Key Competitors Table 24: DermBiont Inc.: Key Competitors Table 25: EnteroBiotix Ltd: Key Competitors Table 26: YSOPIA Bioscience: Key Competitors Table 27: Winclove Probiotics: Key Competitors Table 28: TargEDys: Key Competitors Table 29: Evelo Biosciences, Inc.: Key Competitors Table 30: BiomX: Key Competitors Table 31: Biomica Ltd.: Key Competitors 17 All rights reserved at BIS Research Inc.

  18. Table 32: Scioto Biosciences, Inc.: Key Competitors Table 33: Lactobio A/S: Key Competitors GLOBAL MICROBIOME THERAPEUTICS MARKET 18 All rights reserved at BIS Research Inc.

  19. Disclaimer BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth. This document and its contents are confidential and may not be further distributed, published or reproduced, in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce Information in legal proceedings. Market reports are based on expectations, estimates and projections as of the date such information is available. Any recommendation contained in this report may not be suitable for all investors or businesses. The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to market fluctuations and business, economic and competitive uncertainties and contingencies For more details regarding permission, please contact us: Email: sales@bisresearch.com Tel: +1 510 404 8135 GLOBAL MICROBIOME THERAPEUTICS MARKET 19 All rights reserved at BIS Research Inc.

  20. GLOBAL MICROBIOME THERAPEUTICS MARKET BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686 E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135 Global Delivery Center Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway, Sector 126, Noida, U.P., 201303, India Tel: +91 120 4261540 / 4261544 www.bisresearch.com 20 All rights reserved at BIS Research Inc.

More Related